FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
The FDA has once again issued a complete response letter to Hengrui and Elevar’s applications for camrelizumab and rivoceranib in first-line liver cancer, with manufacturing again being the issue.
The FDA has once again issued a complete response letter to Hengrui and Elevar’s applications for camrelizumab and rivoceranib in first-line liver cancer, with manufacturing again being the issue.
